Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease.

CONTEXT Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of l-arginine, the substrate for nitric oxide synthesis. We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes. OBJECTIVE To explore the role of arginase in sickle cell disease pathogenesis, pulmonary hypertension, and mortality. DESIGN Plasma amino acid levels, plasma and erythrocyte arginase activities, and pulmonary hypertension status as measured by Doppler echocardiogram were prospectively obtained in outpatients with sickle cell disease. Patients were followed up for survival up to 49 months. SETTING Urban tertiary care center and community clinics in the United States between February 2001 and March 2005. PARTICIPANTS Two hundred twenty-eight patients with sickle cell disease, aged 18 to 74 years, and 36 control participants. MAIN OUTCOME MEASURES Plasma amino acid levels, plasma and erythrocyte arginase activities, diagnosis of pulmonary hypertension, and mortality. RESULTS Plasma arginase activity was significantly elevated in patients with sickle cell disease, with highest activity found in patients with secondary pulmonary hypertension. Arginase activity correlated with the arginine-ornithine ratio, and lower ratios were associated with greater severity of pulmonary hypertension and with mortality in this population (risk ratio, 2.5; 95% confidence interval [CI], 1.2-5.2; P = .006). Global arginine bioavailability, characterized by the ratio of arginine to ornithine plus citrulline, was also strongly associated with mortality (risk ratio, 3.6; 95% CI, 1.5-8.3; P<.001). Increased plasma arginase activity was correlated with increased intravascular hemolytic rate and, to a lesser extent, with markers of inflammation and soluble adhesion molecule levels. CONCLUSIONS These data support a novel mechanism of disease in which hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide. The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease.

[1]  D. Vanderjagt,et al.  Serum and urinary amino acid levels in sickle cell disease. , 1997, Journal of tropical pediatrics.

[2]  M. Gladwin,et al.  An emerging role for nitric oxide in sickle cell disease vascular homeostasis and therapy , 2003, Current opinion in hematology.

[3]  E. Mannarino,et al.  Effects of fenofibrate on endothelial function and cell adhesion molecules during post‐prandial lipemia in hypertriglyceridemia , 2003, Journal of clinical pharmacy and therapeutics.

[4]  S. Snyder,et al.  Nitric oxide synthase generates superoxide and nitric oxide in arginine-depleted cells leading to peroxynitrite-mediated cellular injury. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[5]  P. Klatt,et al.  Ca2+/calmodulin-dependent formation of hydrogen peroxide by brain nitric oxide synthase. , 1992, The Biochemical journal.

[6]  M. Gladwin,et al.  Renal Pathology in Hemizygous Sickle Cell Mice , 2002, Toxicologic pathology.

[7]  W. Featherston,et al.  Relative importance of kidney and liver in synthesis of arginine by the rat. , 1973, The American journal of physiology.

[8]  S. Jubelirer,et al.  Primary pulmonary hypertension. Its association with microangiopathic hemolytic anemia and thrombocytopenia. , 1991, Archives of internal medicine.

[9]  Denice K. Tai,et al.  Expression of the liver form of arginase in erythrocytes. , 2002, Molecular genetics and metabolism.

[10]  H. Meurs,et al.  Increased arginase activity underlies allergen‐induced deficiency of cNOS‐derived nitric oxide and airway hyperresponsiveness , 2002, British journal of pharmacology.

[11]  R. Nagel,et al.  Impaired nitric oxide-mediated vasodilation in transgenic sickle mouse. , 2000, American journal of physiology. Heart and circulatory physiology.

[12]  E. Vichinsky,et al.  Patterns of Arginine and Nitric Oxide in Patients With Sickle Cell Disease With Vaso-occlusive Crisis and Acute Chest Syndrome , 2000, Journal of pediatric hematology/oncology.

[13]  K. Feingold,et al.  Regulation of lipid metabolism by cytokines during host defense. , 1996, Nutrition.

[14]  A. Catapano,et al.  Lipoprotein remnants and endothelial dysfunction in the postprandial phase. , 2004, The Journal of clinical endocrinology and metabolism.

[15]  Jubelirer Sj Primary Pulmonary Hypertension: Its Association With Microangiopathic Hemolytic Anemia and Thrombocytopenia , 1991 .

[16]  T. Gotoh,et al.  Regulation of nitric oxide production by arginine metabolic enzymes. , 2000, Biochemical and biophysical research communications.

[17]  Y. Dror,et al.  Arginase activity in erythrocytes of healthy and ill children. , 1970, Clinica chimica acta; international journal of clinical chemistry.

[18]  F. Belfiore [ENZYMATIC ACTIVITIES OF THE BLOOD SERUM IN THALASSEMIA AND IN THALASSODREPANOCYTOSIS]. , 1964, La Riforma medica.

[19]  P. Ganz,et al.  Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans. , 1996, Circulation.

[20]  R. Nagel,et al.  Renal nitric oxide synthases in transgenic sickle cell mice. , 1996, Kidney international.

[21]  M. Gladwin,et al.  Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[22]  E. Closs Expression, regulation and function of carrier proteins for cationic amino acids , 2002, Current opinion in nephrology and hypertension.

[23]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease. , 2011, The American journal of cardiology.

[24]  R. Hebbel,et al.  Tissue factor expression by endothelial cells in sickle cell anemia. , 1998, The Journal of clinical investigation.

[25]  S. Morris,et al.  Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells. , 1998, American journal of physiology. Endocrinology and metabolism.

[26]  W. Valentine,et al.  The arginase activity of erythrocytes and leukocytes with particular reference to pernicious anemia and thalassemia major. , 1957, The Journal of laboratory and clinical medicine.

[27]  D. Vanderjagt,et al.  Reduced cholesterol levels in African-American adults with sickle cell disease. , 2003, Journal of the National Medical Association.

[28]  A. Pathare,et al.  Cytokines in Sickle Cell Disease , 2003, Hematology.

[29]  E. van Marck,et al.  Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? , 1991, The European respiratory journal.

[30]  H. Zar,et al.  Prevalence and reversibility of lower airway obstruction in children with sickle cell disease. , 2001, The Journal of pediatrics.

[31]  M. Gladwin,et al.  Biological activity of nitric oxide in the plasmatic compartment. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[32]  E. Vichinsky,et al.  Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease , 2000, British journal of haematology.

[33]  M. Gladwin,et al.  Hemolytic anemia-associated pulmonary hypertension of sickle cell disease and the nitric oxide/arginine pathway. , 2003, American journal of respiratory and critical care medicine.

[34]  S. Morris,et al.  Decreased arginine bioavailability and increased serum arginase activity in asthma. , 2004, American journal of respiratory and critical care medicine.

[35]  B. Files,et al.  Evidence that L-arginine is a key amino acid in sickle cell anemia — A preliminary report , 1999 .

[36]  M. Gladwin,et al.  Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease. , 2004, Blood.

[37]  S. Ahmad Pulmonary hypertension and right heart failure. , 1995, Chest.

[38]  M. Gladwin,et al.  The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. , 2005, JAMA.

[39]  R. Chou,et al.  Recurrent thromboembolic disease following splenectomy for pyruvate kinase deficiency , 2001, American journal of hematology.

[40]  E. Wayner,et al.  Circulating activated endothelial cells in sickle cell anemia. , 1997, The New England journal of medicine.

[41]  E. Vichinsky,et al.  Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? , 2003, American journal of respiratory and critical care medicine.

[42]  E. Vichinsky,et al.  Hydroxyurea and Arginine Therapy: Impact on Nitric Oxide Production in Sickle Cell Disease , 2003, Journal of pediatric hematology/oncology.

[43]  A. Moss,et al.  Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. , 1972, The New England journal of medicine.

[44]  C. Dampier,et al.  Airway hyperreactivity in children with sickle cell disease. , 1997, The Journal of pediatrics.

[45]  M. Gladwin,et al.  Divergent Nitric Oxide Bioavailability in Men and Women With Sickle Cell Disease , 2003, Circulation.

[46]  A. Adekile,et al.  Th1 and Th2 Cytokine Profiles in Sickle Cell Disease , 2000, Acta Haematologica.

[47]  Hiroyuki Tanaka,et al.  Role of Th2 responses in the development of allergen‐induced airway remodelling in a murine model of allergic asthma , 2003, British journal of pharmacology.

[48]  M. Humbert,et al.  Nitric oxide deficiency in fenfluramine- and dexfenfluramine-induced pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[49]  F. Costa,et al.  The release of nitric oxide and superoxide anion by neutrophils and mononuclear cells from patients with sickle cell anaemia , 1996, British journal of haematology.

[50]  G. Mann,et al.  Membrane Transport of l-Arginine and Cationic Amino Acid Analogs , 2000 .

[51]  R. Nagel,et al.  Effect of fetal hemoglobin on microvascular regulation in sickle transgenic-knockout mice. , 2004, The Journal of clinical investigation.

[52]  A. Duits,et al.  Evidence for a metabolic shift of arginine metabolism in sickle cell disease , 2004, Annals of Hematology.

[53]  Qutayba Hamid,et al.  Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. , 2003, The Journal of clinical investigation.

[54]  A. Varki,et al.  P-selectin mediates the adhesion of sickle erythrocytes to the endothelium. , 2001, Blood.

[55]  D. Stewart,et al.  Short-term pulmonary vasodilation with L-arginine in pulmonary hypertension. , 1995, Circulation.

[56]  S. Morris Regulation of Arginine Availability and Its Impact on NO Synthesis , 2000 .

[57]  T. Mayadas,et al.  The contribution of endothelial cell P-selectin to the microvascular flow of mouse sickle erythrocytes in vivo. , 2004, Blood.

[58]  S. Hazen,et al.  Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[59]  S. Morris Regulation of enzymes of the urea cycle and arginine metabolism. , 2002, Annual review of nutrition.

[60]  H. Arnesen,et al.  Endothelial cell adhesion molecules in healthy adults during acute hyperhomocysteinemia and mild hypertriglyceridemia. , 2004, Clinical biochemistry.

[61]  Guoyao Wu,et al.  Arginine metabolism: nitric oxide and beyond. , 1998, The Biochemical journal.

[62]  P. Niaudet,et al.  Haemolytic uraemic syndrome and pulmonary hypertension in a patient with methionine synthase deficiency , 1999, European Journal of Pediatrics.

[63]  P. Heller,et al.  Pulmonary hypertension in paroxysmal nocturnal hemoglobinuria. , 1992, Chest.

[64]  R. Hebbel,et al.  Differential Expression of E‐ and P‐Selectin in the Microvasculature of Sickle Cell Transgenic Mice , 2004, Microcirculation.

[65]  D. Loukopoulos,et al.  Pulmonary hypertension and right heart failure in patients with beta-thalassemia intermedia. , 1995, Chest.

[66]  M. Gladwin,et al.  Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. , 2002 .

[67]  O. Castro,et al.  Pulmonary hypertension in sickle cell disease: cardiac catheterization results and survival. , 2003, Blood.

[68]  J. Boucher,et al.  Nitric oxide biosynthesis, nitric oxide synthase inhibitors and arginase competition for L-arginine utilization , 1999, Cellular and Molecular Life Sciences CMLS.

[69]  P. V. Rao,et al.  Applied Survival Analysis: Regression Modeling of Time to Event Data , 2000 .

[70]  R. Osarogiagbon,et al.  The Endothelial Biology of Sickle Cell Disease: Inflammation and a Chronic Vasculopathy , 2004, Microcirculation.

[71]  A. Arroliga,et al.  Biochemical reaction products of nitric oxide as quantitative markers of primary pulmonary hypertension. , 1998, American journal of respiratory and critical care medicine.

[72]  T. Gotoh,et al.  Relationship between Arginase Activity and Nitric Oxide Production , 2000 .

[73]  K. Chung,et al.  Cytokines in asthma , 1999, Thorax.